40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +16174554188

With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next generation of RAS therapies, specifically those that can target more mutations, more RAS isoforms, and more indications.

And so, the 5th RAS Targeted Drug Development Summit arrives as the only industry-dedicated, end-to-end forum to accelerate your best-in-class RAS therapies from conception through to commercialization.

As the only industry-dedicated, end-to-end meeting focused on the next-generation of drugs targeting RAS cancers, the 5th RAS Targeted Drug Development Summit will bring together 150+ key opinion leaders to accelerate RAS-targeted drug discovery, advance pre-clinical drugs to clinic, and optimize translational and clinical development.

Industry leaders such as Mirati Therapeutics, Revolution Medicines, Amgen, Novartis, Roche and Loxo Oncology@Lilly will deliver technical, data-led clinical updates and workshops on the translational and clinical development track. On the other hand, expect to hear about promising candidates from the likes of BridgeBio, Biotheryx, Pfizer, and Genentech on the early discovery and pre-clinical track.

Use this exclusive opportunity to network with the key stakeholders and decision makers of the RAS industry including CXOs, VPs, Senior Directors and Global Leads of Oncology, Translational and Clinical Sciences, Chemistry and Biology as well as key academics and oncologists such as Frank McCormick, Channing Der, Chiara Ambrogio, Andrew Aguirre, Mark Awad and Poulikos Poulikakos.

URLs:
Tickets: https://go.evvnt.com/1729218-2?pid=1052
Brochure: https://go.evvnt.com/1729218-3?pid=1052

Prices:
Conference + Workshop Day (Track A or Track B) - Drug Developer Pricing: USD 4946.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Workshop Day (Track A or B) - Solution and Service Provider Pricing: USD 6046.00,
Conference Only - Solution and Service Provider Pricing: USD 3799.00,
Conference + Workshop Day (Track A or B) - Academic Pricing: USD 4246.00,
Conference Only - Academic Pricing: USD 2599.00

 

Arjun Balar, Vice President - Global Clinical Development, Loxo Oncology, Saskia Brachmann, Associate Director and Senior Global Lead, Novartis, Emily Chan, Medical Director, Clinical Research, Amgen, Nicholas Endres, Principal Scientist, Genentech, Antreas Hindoyan, Director, Clinical Biomarkers and Diagnostics, Amgen , Greg Jones, Principal Scientist, Pfizer, Robert Norgard, Senior Scientist, Boehringer Ingelheim, Ahmadur Rahman, Senior Director - Clinical, Global Oncology, Research and Development Science Lead, Roche, Chinatsu Sakata-Sakurai, Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas Pharma, Andrea Wang-Gillam, Chief Medical Officer, Jacobio Pharmaceutical, Allison Zavitz, Lifecycle Leader, KRAS, Roche, Ashita Nayak, Executive Director, Marketing, Amgen, Steven Howard, Director, Chemistry, Astex Therapeutics, Ida Aronchik, Senior Director - Translational Sciences, Revolution Medicines, Pedro Beltran, Senior Vice President and Head of Biology ,BridgeBio and Oncology Therapeutics, Bridge Bioscience, Charly Chahwan, CSO, SyntheX, Aparajita, Chourasia Vice President, Biology, BioTheryx, Louis Denis, Chief Medical Officer, Verastem, Steven Fruchtman, President and Chief Executive officer, Chief Medical Officer, Onconova Therapeutics, Rie Schultz Hansen, CSO, Aelin Therapeutics, Lingyan Jiang, Senior Scientist II, Revolution Medicines, Shohei Koide, Co-Founder of Aethon Bio and Professor, Grossman School of Medicine NYU Langone Health, Hue Lam Vice, President of Preclinical Development, Affini-T Therapeutics, Shivani Malik, Associate Director, Kura Oncology, Andrew Norris, Co-Founder, CSO, BCN Biosciences, Jonathan Pachter, Chief Scientific Officer, Verastem, Gary Piazza Chief Scientist, ADT Pharmaceutical LLC and Director, Cancer Research Center Auburn University, Krishnaraj Rajalingam, Founder, KHR Biotec and Head of Cell Biology Unit, University of Mainz, Debra Ryan, Director, Medical Strategy, Mirati Therapeutics, Hugh Salter, Chief Scientific Officer and Vice President - Strategy and Translation, Anocca AB, Said Sebti, Co-Founder, Prescient Therapeutics and Associate Director of Basic Research, VCU Massey Cancer Center, Sunanda Singh, Founder and Chief Executive Officer, Singh Biotechnology, Giovanni Spagnolli, Co-Founder and Chief Technology Officer, Sibylla Biotech, Ali Tavassoli, CSO, Curve Therapeutics, Greg Verdine, Co-Founder, President, Chief Executive and Technology Officer, LifeMine Therapeutics, Kevin Yang, Associate Director of Translational Research, Revolution Medicines, Michelle Zhang, Chief Scientific Officer, Ikena Oncology, Terri Conneran, Founder, KRAS Kickers